Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach

References

• Bunnapradist S, Sampaio MS, Wilkinson AH, et al. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Am J Nephrol. 2014;40:184–190
   PubMedGoogle Scholar
• Goubella A, Broeders N, Racapé J, et al. Patient and graft outcome in current era of immunosuppression: A single centre pilot study. Acta Clin Belg. 2014. [Epub ahead of print]. doi:https://doi.org/http://dx.doi.org/10.1179/2295333714Y.0000000078
   Google Scholar
• Langone A, Shihab F, Pankewycz O, et al. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation. Clin Transplant. 2014;28:961–967
   PubMedGoogle Scholar
• The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029–1037
   PubMed Web of Science ®Google Scholar
• Kaminska J, Glyda M, Sobiak J, Chrzanowska M. Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant percipients with renal impairment. Arch Med Sci. 2012;8:88–96
   PubMed Web of Science ®Google Scholar
• Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet. 2013;52:303–331
   PubMed Web of Science ®Google Scholar
• Mamelok R. From mechanisms to long-term benefits. Transplantation. 2005;79:43–44
   PubMedGoogle Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58
   PubMed Web of Science ®Google Scholar
• Jeong H, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. J Am Soc Nephrol. 2007;2:184–191
   Google Scholar
• Shah T, Tellez-Corrales E, Yang JW, et al. The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. Ther Drug Monit. 2011;33:45–49
   PubMedGoogle Scholar
• Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: A consequence of local GI toxicity? Transplant Proc. 2007;39:88–93
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079–1083
   PubMed Web of Science ®Google Scholar
• Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation. 2006;81:1290–1297
   PubMed Web of Science ®Google Scholar
• Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005;19:199–206
   PubMed Web of Science ®Google Scholar
• Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: A multicenter, double-blind, randomized study. Transplantation. 2011;91:470–478
   PubMedGoogle Scholar
• Reyes H, Hernández AM, Valverde S, et al. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplant. 2010;14:746–752
   PubMed Web of Science ®Google Scholar
• Musuamba FT, Mourad M, Haufroid V, et al. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol. 2012;52:1833–1843
   PubMed Web of Science ®Google Scholar
• Zhao W, Fakhoury M, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol. 2010;50:1280–1291
   PubMed Web of Science ®Google Scholar
• de Winter BC, Mathot RA, van Hest RM, van Gelder T. Therapeutic drug monitoring of mycophenolic acid: Does it improve patient outcome? Expert Opin Drug Metab Toxicol. 2007;3:251–261
   PubMed Web of Science ®Google Scholar
• Hummel M, Yonan N, Ross H, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant. 2007;21:18–23
   PubMedGoogle Scholar
• Hohage H, Zeh M, Heck M, Gerhardt UW, Welling U, Suwelack BM. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc. 2005;37:1748–1750
   PubMedGoogle Scholar
• Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev. 2011;25:47–57
   Google Scholar
• Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS. Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol. 2013;53:393–402
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• Beal SL. NONMEM Users Guides. California: NONMEM Project Group, University of San Francisko; 2006
   Google Scholar
• Milovanovic JR, Jankovic SM. Factors influencing carbamazepine PK in children and adults: Population PK-analysis. Int J Clin Pharmacol Ther. 2011;49:428–436
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–512
   PubMedGoogle Scholar
• Zhou PJ, Xu D, Yu ZC, Wang XH, Shao K, Zhao JP. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet. 2007;46:389–401
   PubMed Web of Science ®Google Scholar
• Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal p-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20:2468–2480
   PubMed Web of Science ®Google Scholar
• Staatz CE, Duffull SB, Kiberd B Fraser AD, Tett SE. Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol. 2005;61:507–516
   PubMed Web of Science ®Google Scholar
• van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871–880
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071–1081
   PubMed Web of Science ®Google Scholar
• Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82:603–611
   PubMed Web of Science ®Google Scholar
• Choi JS, Choi I, Choi DH. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine. Pharmacol Rep. 2013;65:1422–1430
   PubMed Web of Science ®Google Scholar
• Cross NB, Webster AC, Masson P, O'connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: Systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009;88:7–18
   PubMed Web of Science ®Google Scholar
• Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-{beta}1 plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol. 2001;12:822–827
   PubMed Web of Science ®Google Scholar
• Madsen JK, Sorensen SS, Hansen HE, Pedersen EB. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant. 1998;13:2327–2334
   PubMedGoogle Scholar
• Vethe NT, Midtvedt K, Asberg A, Amundsen R, Bergan S. Drug interactions and immunosuppression in organ transplant recipients. Tidsskr Nor Laegeforen. 2011;131:2000–2003
   PubMedGoogle Scholar
• Boom H, Mallat MJ, de Fijter JW, Paul LC, Bruijn JA, van Es LA. Calcium levels as a risk factor for delayed graft function. Transplantation. 2004;77:868–873
   PubMedGoogle Scholar
• Kim H, Long-Boyle J, Rydholm N, et al. Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. J Clin Pharmacol. 2012;52:1665–1675
   PubMed Web of Science ®Google Scholar
• van Hest RM, van Gelder T, Vulto AG, Shaw LM, Mathot RA. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009;48:463–476
   PubMed Web of Science ®Google Scholar
• de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009;36:541–564
   PubMed Web of Science ®Google Scholar
• Van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005;44:1083–1096
   PubMed Web of Science ®Google Scholar
• Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100–104
   PubMed Web of Science ®Google Scholar